Blood
Articles in this Issue
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis
Abstract We previously demonstrated that reduced intrinsic electron transport chain (ETC) activity predicts and promotes sensitivity to the B-cell lymphoma 2 (BCL-2) antagonist, vene...
Acute erythroid leukemia or acute myeloid leukemia with mutated <i>TP53</i>? The battle of phenotype versus genotype
Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin B-cell lymphoma that defies cures in most patients. Over the last decade, significant advances have been made in our understandi...
Sequential epigenetic therapy in AML
Ferroptosis regulates hemolysis in stored murine and human red blood cells
Abstract Red blood cell (RBC) metabolism regulates hemolysis during aging in vivo and in the blood bank. However, the genetic underpinnings of RBC metabolic heterogeneity and extra...
Mosunetuzumab next up to bat … is it a home run?
Heme fuels venetoclax resistance in multiple myeloma
Unraveling MCL biology to understand resistance and identify vulnerabilities
Abstract Mantle cell lymphoma (MCL) is a rare (5%-7%), aggressive B-cell non-Hodgkin lymphoma with well-defined hallmarks (eg, cyclin D1, SOX11), and its expansion is highly dependen...
Frontline management of mantle cell lymphoma
Abstract Despite many recent therapeutic advances, mantle cell lymphoma (MCL) remains a largely incurable disease. Treatments for patients with relapsed/refractory (R/R) disease are...
QTLs unlock RBC storage hemolysis secrets
High-risk MCL: recognition and treatment
Abstract Significant progress in determining the molecular origins and resistance mechanisms of mantle cell lymphoma (MCL) has improved our understanding of the disease’s clinical di...
Treatment of relapsed/refractory MCL
Abstract Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma that is clinically characterized by its heterogeneous behavior, with courses ranging from indolen...
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation
Abstract Initial clinical trials with drugs targeting epigenetic modulators, such as bromodomain and extraterminal protein (BET) inhibitors, demonstrate modest results in acute myelo...
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Abstract Mosunetuzumab, a CD20×CD3 T-cell engaging bispecific antibody, redirects T cells to eliminate malignant B cells. We present updated efficacy and safety data of a pivotal pha...
Novel CAR T cells to combat antigen escape in AML
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML
Abstract CD70 has emerged as a promising target in acute myeloid leukemia (AML), and we have previously demonstrated the potency of an optimized CD70-targeted ligand-based chimeric a...